Isis Reports In-Line Loss - Analyst Blog
Isis Pharmaceuticals Inc. (ISIS) reported a net
loss of 3 cents per share in the first quarter of 2013, in line
with the Zacks Consensus Estimate. The loss was narrower than the
year-ago loss of 23 cents, benefiting from higher revenues.
Revenues increased 86.6% to $43.4 million, missing the Zacks
Consensus Estimate of $52 million. Revenues include license fees,
milestone-related payments and other payments.
In the first quarter of 2013, the company received a milestone
payment of $25 million from its partner Sanofi
(SNY). The payment was received following the US approval of
Kynamro (mipomersen sodium) for the treatment of familial
hypercholesterolemia (FH).
In Feb 2013, Isis Pharma received a $7.5 million milestone payment
from GlaxoSmithKline (GSK). The payment primarily
relates to the initiation of a phase II/III clinical study of
ISIS-TTR. The study will span 15 months enrolling 200 patients.
Isis is developing ISIS-TTR in collaboration with Glaxo for the
potential treatment of transthyretin (TTR) amyloidosis.
Operating expenses remained flat during the first quarter of 2013
at $41.7 million. Research and development expenses decreased 1.0%
to $38.3 million and general and administrative expenses were up
15.0% to $3.4 million.
We note that in the second quarter of 2013, Isis Pharma is expected
to record significant milestone revenues. The company has already
received an upfront payment of $30 million from the Huntington's
disease (HD) collaboration. Additionally, Isis Pharma is also
expected to record $3.5 million of milestone payment related to
ISIS-SMN.
Isis Pharma boasts of a promising pipeline of 28 candidates with
several candidates expected to reach the market by 2017. Key
near-term events include: release of top-line data from the phase
II study evaluating ISIS-APOCIII for the treatment of severe
hypertriglyceridemia and data from a phase II study evaluating the
use of ISIS-CRP in rheumatoid arthritis (RA) patients.
Meanwhile, Isis Pharma has also announced its plans to initiate a
public offering of 10.35 million shares of common stock including
an over-allotment option for 1.35 shares.
Isis Pharma currently carries a Zacks Rank #2 (Buy). Stocks such as
Lannett Company, Inc. (LCI) look more attractive
in the pharma sector with a Zacks Rank #1 (Strong Buy).
GLAXOSMITHKLINE (GSK): Free Stock Analysis Report
ISIS PHARMACEUT (ISIS): Free Stock Analysis Report
LANNETT INC (LCI): Free Stock Analysis Report
SANOFI-AVENTIS (SNY): Free Stock Analysis Report
To read this article on Zacks.com click here.
London Clubs (AMEX:LCI)
過去 株価チャート
から 6 2024 まで 7 2024
London Clubs (AMEX:LCI)
過去 株価チャート
から 7 2023 まで 7 2024
Real-Time news about Lannett CO (アメリカ証券取引所): 0 recent articles
その他のLondon Clubsニュース記事